Ryan Gately

Ryan Gately

Auto-generated profile, based on publicly available information

Ryan Gately

Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Kidney International Reports
Verified
Journal Article
Open access
RGRyan Gately
Ryan Gately
EMElasma Milanzi
Elasma Milanzi
WLWai Lim
Wai Lim
ATArmando Teixeira-Pinto
Armando Teixeira-Pinto
PCPhil Clayton
Phil Clayton
GWGermaine Wong
Germaine Wong
BK polyomavirus-associated nephropathy (BKPyVAN) is associated with graft dysfunction and loss; however, knowledge of immunosuppression reduction strategies and long-term graft, and patient outcomes across the disease spectrum is lacking. This cohort study included 14,697 kidney transplant recipients in Australia and New Zealand (2005-2019), followed for 91,306 person years. BKPyVAN occurred in 460 recipients (3%) at a median posttransplant time of 4.8 months (interquartile range, 3.1-10.8). Graft loss (35% vs. 21%, P < 0.001), rejection (42% vs. 25%, P < 0.001), and death (18% vs. 13%, P = 0.002) were more common in the BKPyVAN group. The most frequent changes in immunosuppression after BKPyVAN were reduction (≤50%) in tacrolimus (172, 51%) and mycophenolate doses (134, 40%), followed by the conversion of mycophenolate to leflunomide (62, 19%) and tacrolimus to ciclosporin (20, 6%). Factors associated with the development of BKPyVAN included (adjusted hazard ratio [HR]; 95% confidence interval) male sex (1.66; 1.34-2.05), recipient age (≥70 vs. <20 [2.46; 1.30-4.65]), recipient blood group (A vs. B [2.00; 1.19-3.34]), donor age (≥70 vs. <20 [2.99; 1.71-5.22]), earlier era (1.74; 1.35-2.25), donor/recipient ethnic mismatch (1.52; 1.23-1.87), tacrolimus use (1.46; 1.11-1.91), and transplantation at a lower-volume transplant center (1.61; 1.24-2.09). The development of BKPyVAN was associated with an increased risk of all-cause (1.75; 1.46-2.09) and death-censored graft loss (2.49; 1.99-3.11), but not mortality (1.15; 0.91-1.45). BKPyVAN is associated with an increased risk of all-cause and death-censored graft loss, but not death. Interventional trials are urgently needed to evaluate the efficacy of immunosuppression reduction and novel strategies to minimize the adverse outcomes associated with BKPyVAN.

7 February 2017 in Nephrology
Verified
Journal Article
Closed access
PDF file
RGRyan Gately
Ryan Gately
ASAye San
Aye San
JKJagadeesh Kurtkoti
Jagadeesh Kurtkoti
APAlan Parnham
Alan Parnham

1 January 2021 in Kidney International Reports
Verified
Journal Article
Open access
RGRyan Gately
Ryan Gately
GLGregory Lock
Gregory Lock
CPChirag Patel
Chirag Patel
JCJohn Clouston
John Clouston
CHCarmel Hawley
Carmel Hawley
Andrew MallettAndrew Mallett
Andrew Mallett

20 September 2023 in Kidney International
Verified
Journal Article
Closed access
YWYue Wu
Yue Wu
MDMichael Dymock
Michael Dymock
RGRyan Gately
Ryan Gately
JMJulie A. Marsh
Julie A. Marsh
CHCarmel Hawley
Carmel Hawley
TSThomas L. Snelling
Thomas L. Snelling

7 April 2025 in HLA
Verified
Journal Article
Open access
RGRyan Gately
Ryan Gately
ATAnne Taverniti
Anne Taverniti
NWNarelle Watson
Narelle Watson
ATArmando Teixeira‐Pinto
Armando Teixeira‐Pinto
EOEsther Ooi
Esther Ooi
WLWai H. Lim
Wai H. Lim
Deceased donor kidney allocation relies on HLA compatibility at the antigen level, as optimal matching reduces the risk of acute rejection. Whether HLA allele‐level mismatches improve, the prediction of acute rejection after transplantation remains unclear. Using data from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) from 2017 to 2020, HLA antigenic and allelic mismatches between recipients and deceased donors were calculated with imputation of two‐field allelic equivalents undertaken where required. The discordance between antigen and allele mismatches was calculated, and oblique random survival forest models were used to predict acute rejection. Predictive performance of antigen (HLA‐A, ‐B, ‐DRB1 and ‐DQB1), allele (HLA‐A, ‐B, ‐DRB1 and ‐DQB1) and extended allele (HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQA1 and ‐DQB1) models was examined using concordance index and integrated Brier scores, with variable importance calculated using permutation‐based methods. Among 2644 recipients followed for a median of 1.7 years, 521 recipients (20%) experienced acute rejection. Discordant numbers of antigenic and allelic mismatches occurred in 8%, 9%, 24% and 17% of HLA‐A, ‐B, ‐DRB1 and ‐DQB1 loci, respectively. Predictive performances were similar across all models, with concordance indices of 0.62–0.63 and integrated Brier scores of 0.09. HLA‐DRB1 and ‐DQB1 mismatches were the strongest predictors of acute rejection across models. In patients matched at the HLA‐DRB1 or ‐DQB1 antigen, those with allelic mismatches had similar incidences of rejection compared to those without. Allelic‐level assessment of HLA compatibility did not improve the prediction of acute rejection and may disadvantage certain recipients by reclassifying them into higher mismatch categories in allocation algorithms without providing clear clinical benefit.

11 May 2025 in Clinical Transplantation
Verified
Journal Article
Open access
TSTahira Scott
Tahira Scott
JAJasna Aleksova
Jasna Aleksova
CHCarmel Hawley
Carmel Hawley
MKMina Khair
Mina Khair
HKHarpreet Kaur
Harpreet Kaur
GEGrahame Elder
Grahame Elder
Background: Patients with kidney failure have elevated fracture risk that remains high following kidney transplantation. This study aimed to assess whether dual‐energy x‐ray absorptiometry‐derived advanced hip analysis (AHA) and the trabecular bone score (TBS) improve bone mineral density (BMD)‐based post‐transplant fracture prediction.Methods: Patients receiving kidney‐only or simultaneous pancreas‐kidney (SPK) transplants underwent immediate post‐transplant dual‐energy x‐ray absorptiometry to provide BMD, the TBS, and AHA parameters; femoral neck, calcar, and shaft cortical thickness (CTh), and femoral neck buckling ratio (BR), an index of structural instability. Patients received treatment to reduce post‐transplant BMD loss, using an established risk algorithm. Hazard ratios were determined using Kaplan–Meier and Cox proportional hazard models.Results: Of 357 transplant recipients, 289 (83%) received a kidney‐only transplant. There were 83 incident fractures over a median of 4.4 years (IQR: 2.5–5.5). Fracture was associated with type 1 diabetes mellitus (p < 0.001), former smoking (p = 0.006), lower 25‐hydroxyvitamin D (p = 0.003), BMD at total proximal femur and neck of femur (p < 0.001) and spine (p = 0.008), lower CTh at the calcar (p = 0.005) and shaft (p = 0.023), higher BR (p = 0.016) and lower TBS (p = 0.047). Following multivariable adjustment, type 1 diabetes mellitus, 25‐hydroxyvitamin D, smoking, and femoral neck BMD remained significant. Using the BMD‐based risk algorithm, inclusion of the BR improved the model fit.Conclusion: BMD, the TBS, and AHA parameters are associated with incident fracture in kidney‐only and SPK transplant recipients. Pre‐transplant smoking, lower 25‐hydroxyvitamin D and BMD are potentially modifiable factors that could reduce post‐transplant fracture risk.